Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: GSK | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: GSK

Continued price and contracting pressures affect respiratory sales

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

GSK

3Q Revenues: £5.6 billion (-10%)*
 
3Q Earnings: £385 (earnings were £1.0 billion in 3Q13)
 
YTD Revenues: £16.8 billion (-11%)
 
YTD Earnings: £1.8 billion (earnings were £3.1 billion YTD13)
 
Comments: Pharmaceutical sales were £3.7 billion (-4%) and vaccine sales were flat at £922 million, with U.S. sales down 10% to £1.3 billion, impacted by continued price and contracting pressures affecting respiratory sales (-17%). Established product sales were down 14% to £724 million in the quarter, reflecting generic competition to Lovaza in the U.S., down 58%, and continuing generic competition to a number of products across the portfolio, including Seroxat/Paxil, down 11% and Valtrex, down 29%. Following the divestment of its oncology portfolio and the impact of the U.S. respiratory market, a new restructuring program will rescale commercial operations, global support functions and relevant R&D/manufacturing across pharmaceuticals and is expected to deliver £1 billion of new annual cost savings over the next 3 years, which will also impact headcount.

     *All results reported at constant exchange rate (CER).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters